Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tozorakimab + dapagliflozin
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
**Tozorakimab + dapagliflozin** is a combination investigational therapy consisting of tozorakimab, a monoclonal antibody designed to neutralize the cytokine interleukin-33 (IL-33), and dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor primarily used for diabetes and chronic kidney disease. Tozorakimab is developed for the treatment of diabetic kidney disease, among other inflammatory and respiratory conditions, with the intent of addressing renal inflammation and damage by targeting IL-33 pathways[5][13][8]. Dapagliflozin acts by inhibiting SGLT2 in the renal proximal tubule, reducing glucose reabsorption and exerting renal and cardiovascular protective effects. The combination is studied for the potential additive or synergistic effect on renal outcomes in diabetic kidney disease[5].
- Other names
- tozorakimabdapagliflozinFarxiga
02
Targets
IL33 (IL-33)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on tozorakimab + dapagliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tozorakimab + dapagliflozin.